Loading…
Economic and management consulting firm providing litigation, regulatory and strategy consulting to corporations and law firms.
Economic and management consulting firm providing litigation, regulatory and strategy consulting to corporations and law firms.
Bills clients by the hour for consultants and expert time, so how fully its staff are booked and how many large cases it has decide the year. Much of the work comes from law firms hiring economists to testify or advise on antitrust and merger reviews, with well-known academic experts affiliated with it.
Moat: narrow (brand, process know-how). Reputation for rigorous economic analysis in high-stakes litigation and antitrust matters drives repeat business.
Headquarters: Boston, Massachusetts · Founded: 1965 · Employees: 959
Size CRA International (CRAI) is a United States Industrials company (Miscellaneous Commercial Services) with a market value of $1.24B, the 2117th largest of 3,117 United States companies the cockpit tracks. Shares closed at $197.66 on 6 Nov 2026.
Performance Over six months the shares gained 41.6%, against -17.5% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 11.5% over the last twelve months (peer median +11.9%); the operating margin is 10.0% (peer median 9.3%).
Valuation It trades at 22.4× forward earnings against a peer median of 22.9× (8th cheapest of 15).
Capital Return on invested capital runs 6.0 points above its cost of capital (7.5% WACC).
Short interest Short interest is 5.2% of the free float (15 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $795M | $752M | $687M | $624M | $591M |
| Revenue growth | — | +9% | +10% | +6% | — |
| Gross profit | $217M | $218M | $196M | $172M | $169M |
| EBITDA | $108M | $113M | $97.4M | $82.4M | $84.5M |
| Net income | $49.3M | $54.7M | $46.5M | $38.3M | $43.5M |
| Free cash flow | -$27.7M | $18.6M | $33.1M | $57.7M | $20.3M |
| Capital expenditure | $6.00M | $3.87M | $16.6M | $2.37M | $3.81M |
| Total debt | $304M | $127M | $103M | $109M | $122M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| CRA International CRAI | $1.24B | +42% | +11% | 10% | 22.4× | n/a |
| FTI Consulting FCN | $5.33B | +19% | +8% | 10% | 18.7× | -3.6% |
| Marsh McLennan MRSH | $97.4B | +25% | +8% | 24% | 18.2× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CRAI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.3% | -2.4% | 4th highest of 21 |
| 6-month return | +41.6% | -17.5% | 3rd highest of 21 |
| Distance from 52-week high | -13.0% | -36.9% | 3rd highest of 21 |
| Revenue growth (TTM) | +11.5% | +11.9% | 11th highest of 21 |
| Operating margin | 10.0% | 9.3% | 10th highest of 21 |
| Forward P/E | 22.4× | 22.9× | 8th cheapest of 15 |
| ROIC minus cost of capital | +6.0 pp | -0.0 pp | 6th highest of 21 |
| EV / EBITDA | 14.1× | 8.1× | 2nd most expensive of 7 |
| Net debt / EBITDA | 2.6× | -0.1× | 2nd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CRA International CRAI | United States | $1.24B | +42% | +11% | 10% | 22.4× | n/a | n/a |
| Shanxi Huaxiang 603112.SS | China | $1.24B | -26% | +9% | 11% | 12.1× | 1.4% | +16.2% |
| Vcanbio Cell & Gene Engineering 600645.SS | China | $1.23B | -32% | -6% | 12% | 45.0× | 11.0% | +1.9% |
| Jadard Technology 688252.SS | China | $1.22B | -12% | +6% | 12% | 23.8× | 13.3% | +31.3% |
| Shanghai MicroPort EP Medtech 688351.SS | China | $1.27B | -23% | +20% | 3% | 135.2× | 41.7% | +26.7% |
| Bajaj Mobility BMAG.SW | Switzerland | $1.28B | +86% | -47% | -44% | 10.4× | n/a | n/a |
| Resolute Holdings Management RHLD | United States | $1.20B | +39% | +10% | 9% | n/a | 26.0% | n/a |
| China East Education 0667.HK | Hong Kong | $1.18B | -18% | +16% | 22% | 8.4× | -6.1% | +4.1% |
| Shenzhen Aoni Electronic 301189.SZ | China | $1.18B | -17% | +139% | 2% | n/a | n/a | n/a |
| Beijing Haitian Ruisheng Science Technology 688787.SS | China | $1.17B | -1% | +34% | 4% | 163.5× | n/a | n/a |
| SBT Ultrasonic Technology 688392.SS | China | $1.16B | -19% | +42% | 17% | 52.9× | n/a | n/a |
| Suzhou Novoprotein Scientific 688137.SS | China | $1.33B | +161% | +8% | -62% | n/a | n/a | n/a |
| EMTEK (Shenzhen) 300938.SZ | China | $1.16B | -44% | +11% | 27% | 33.1× | n/a | n/a |
| Central Mine Planning & Design Institute CMPDI.NS | India | $1.34B | -15% | +10% | 33% | n/a | 4.0% | +18.7% |
| Nittetsu Mining 1515.T | Japan | $1.34B | +10% | +13% | 9% | n/a | n/a | n/a |
| TKC 9746.T | Japan | $1.34B | +21% | +14% | 22% | 18.1× | -9.9% | +4.2% |
| Changchun Up Optotech 002338.SZ | China | $1.34B | -39% | +22% | 2% | 43.4× | n/a | n/a |
| Naruida Technology 688522.SS | China | $1.14B | -28% | +20% | 14% | 22.0× | n/a | n/a |
| SBS 2384.T | Japan | $1.38B | +32% | +22% | 6% | 14.1× | -8.2% | +13.8% |
| FESCO 600861.SS | China | $1.11B | -18% | +4% | 1% | 10.4× | n/a | n/a |
| China Security 600654.SS | China | $1.39B | -31% | -30% | -1% | n/a | 56.7% | +0.4% |